Quantum Genomics S.A. (QNNTF) Research

Quantum Genomics S.A., a biopharmaceutical enterprise headquartered in Paris, France, was established in 2005. The company specializes in advancing therapeutic solutions for cardiovascular ailments. Its drug development efforts are anchored in the brain aminopeptidase A inhibition (BAPAI) platform, primarily targeting hypertension (high blood pressure) and heart failure. Among its pipeline, firibastat is a notable candidate, currently undergoing a crucial Phase III study as a standalone treatment for high blood pressure, and is also progressing through clinical trials for heart failure. Furthermore, Quantum Genomics is developing QGC011 for combination therapy in hypertension, alongside QGC006 and QGC606, which are designed to address both hypertension and heart failure.

Market snapshot

Symbol
QNNTF
Price
$0.10
Day change
0.00%
Market cap
$5.0M
P/E ratio
-0.57x
52-week range
0.1-0.1
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BetterLife Pharma Inc. (BETRF)
  • Chimeric Therapeutics Limited (CHMMF)
  • Curative Biotechnology, Inc. (CUBT)
  • Glow Lifetech Corp. (GLWLF)
  • LianBio (LIANY)
  • NanoSphere Health Sciences Inc. (NSHSF)
  • PharmaTher Holdings Ltd. (PHRRF)
  • Theralink Technologies, Inc. (THER)

Open Quantum Genomics S.A. (QNNTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.